- Hifas da Terra (HDT), multinational biotech leader in the development of natural products for human health based on medicinal fungi, evaluates the impact of its formula ‘Mico-Mama 2.0’ in patients with breast cancer by implementing a New clinical trial promoted by the Galicia Sur Health Research Institute (IISGS). This essay, which is part of the collaborative project Microimmunomama Led by HDT since 2019, it will measure several health and quality of life parameters in more than 100 breast cancer patients. Thus, this oncological clinical study is a milestone in research with medicinal fungi in the fight against breast cancer.
- The clinical trial is carried out in the Vigo University Hospital Complex (Chuvi), belonging to the health area of Vigo and headquarters of the IIS Galicia Sur. He Dr. Esteban Castelao, principal researcher, is responsible, together with Dr. Víctor Muñoz, of the Group of Genetic Oncology, Radiobiology and Radio of the Research Institute to which the hospital belongs. The essay, which is part of the ‘Microimmunomama’lideaded by HDT and of which IIS Galicia Sur is a member, has been funded by the Spanish Ministry of Science and Innovation through the Challenges Collaboration Program. Microimmunomama is a long research work on medical applications of medicinal fungi in breast cancer.
-
Hifas da Terra was founded in 1998 by the hand of Catalina Fernández de Ana Portela, Biologist, myóglaga and in a doctoral program in Oncological Clinical Research at the University of Santiago de Compostela. The HDT company, a Pioneer biotechnological project Born in Galicia, he has become International leader in the development of natural products for human health based on medicinal fungi.
Great bet of Hifas da Terra (HDT) for the research of natural products in human health with a new clinical trial in breast cancer within the last phase of the microimmunomama project that leads since 2019. It is a collaborative project, in which the IIS Galicia Sur and the Leitat Technology Center as partners, which consists in the development of new nutritional supplements capable of modulating the immune response and the intestinal microbiota, and the study of their Benefits in breast cancer.
The main hypothesis of the trial is that Micama 2.0 supplementation can improve the immune response of patients with breast cancer and help the regulation of intestinal microbiota altered by oncological treatments.
It is a double-blind randomized clinical trial controlled with placebo that aims to evaluate the efficacy and health benefits of the mycum-mama 2.0 product of Hifas da Terra in breast cancer patients. MICO-MAMA 2.0 will be administered once the Oncological Standard Treatment (chemotherapy and radiotherapy) has ended. The intestinal microbiota and several parameters of the immune system of these patients will be exhaustively monitored. The essay will recruit between 100 and 120 patients with breast cancer of different subtypes (luminal A, luminal B, triple negative etc.) and will include the monitoring of the intestinal microbiota through innovative molecular multi-momic platforms.
The natural product developed by Hifas da Terra is expected to also potentially reduce the side effects of these treatments, such as immunosuppression, fatigue, neurological deterioration or peripheral neuropathy, thus improving the quality of life of these patients. This study can help define in the future a possible use of myco-mama 2.0 in the clinical management of breast cancer.
It should be noted that, in a first phase of the clinical study it is sought to define The relationship between microbiome and cancer Mama, a relationship that may have implications in the future development of diagnostic tools and/or in the implementation-modulation of therapeutic interventions. In this phase they will participate approximately 280 women, 140 just patients Diagnosed breast cancer in stages I, II or III They will receive oncological medical treatment and 140 women without breast cancer.
Mico-Mama 2.0
Modern science has discovered in medicinal fungi they have various activities with therapeutic potential, mainly antitumor, immunomodulators and anti -inflammatory. Therefore, aware of the large number of qualities that enclose these fungi, Hifas da Terra has not hesitated to put his research at the service of one of the great medical problems of the moment, breast cancer.
Mico-Mama 2.0 It is one Vanguard formula developed by Hifas da Terra with immunomodulatory natural active ingredients, such as beta-glucans with prebiotic function, terpenes and probiotics, inter alia.
The aforementioned components are related to the anti -cancer properties of medicinal fungi. Mico-Mama 2.0 is part of the line HDT Onco Care, whose development is the result of many years of intense scientific research carried out in collaboration with institutions and organizations recognized nationally and internationally. These products contain the highest levels of active compounds ever produced, compared to any product based on medicinal fungi. Each formulation combines different medicinal fungi with complementary and synergistic effects to provide the greatest health benefits for each type of cancer.
Breast, immunity and intestinal microbiota cancer
In Spain, according to the data provided by the Spanish Society of Medical Oncology and the Spanish Association against Cancer, it is estimated that One in eight women will suffer from breast cancer at some point in his life. In 2019 it was the second cancer with the highest incidence in Spain, with 33,307 new cases. This type of tumor usually appears between 35-80 years, being the strip 45-65 years of the highest incidence, being the moment in which hormonal changes occur in periods of peri and post menopause. An incidence curve that continues to increase as the woman ages.
The diagnostic improvements and treatments have increased the survival of these patients. However, breast cancer remains, today, the tumor most frequently responsible for mortality in women.
The current breast cancer treatment forms are surgery, chemotherapy, radiotherapy and immunotherapy. Within these treatments the immune function has a transcendental role in the patient's clinical response. All those agents that can help this immune function be increased would be agents that can play an important role as an adjunct to standard treatment. After the diagnosis, most patients are treated with antineoplastic therapy and are immunosuppressed. For example, chemotherapeutic myelosuppression, the decrease in the activity of the bone marrow associated with chemotherapy that leads the patient to an immunosuppressed and fatigue state, is one of the most serious side effects of chemotherapy. This often truncated treatment and requires hospitalization before complete therapeutic effects can be achieved. Several studies propose that the reduction of myelosuppression would allow a better response to chemotherapy.
The Benefits of medicinal fungi extracts, which can be found in some nutraceutical and have been published in different Essays with cancer patients have proven to improve the quality of life of these patients. Although evidence is still limited and more studies are necessary at the clinical level, several works suggest that fungi could be potentially used in the future to optimize the effect of standard cancer treatments, such as chemotherapy and radiotherapy. According to scientific evidence, immune stimulation during cancer can be beneficial in terms of tumor regression and patient survival.
In addition, immunity has a close relationship with the state of the intestinal microbiota. It has been studied that The microbiota of women with breast cancer differs from those healthy, indicating that certain bacteria can be associated with the development of cancer and different responses to treatments, such as chemotherapy. Therefore, the most recent studies suggest that Microbiota alterations could be a new risk factor in the appearance and progression of breast cancer. Thus, the role of the intestinal microbiota is increasingly relevant in oncology and the beneficial impact of its possible modulation is unknown.
In recent years it has been found that The intestinal microbiota can be modulated by compounds with prebiotic activity such as those from certain medicinal fungi species.
Based on this background, the microimmunomama project was raised as the development and functional validation of a new nutraceutical to which myco-mama 2.0 has been called, formulated from extracts of medicinal fungi, with potential capacity to influence the intestinal microbiota and stimulate the immune response, improving the evolution and recovery of patients who have suffered breast cancer.
Hifas da Terra, research as a company pillar
Medicinal fungi are fascinating substance factories with positive effects on human health. A single species can contain hundreds of bioactive substances. According to science, medicinal fungi have various antitumor, immunomodulatory, anti -inflammatory, antioxidant, antiviral, antibacterial, antiparasitic, hepatoprotective or antidiabetic activities. Properties that have allowed them to adapt perfectly to the environment in which they are and be able to overcome any adversity without moving.
Catalina Fernández de Ana Portela He is responsible for the success of the Hifas da Terra company that, as Founder and President, applies a "know-how", based on more than 20 years of experience, along with a broad and international team of experts. To know the origin of the company it is necessary to go back to 1998 when he was born. Hifas da Terra It is a Biotech that is based on research and innovation, with a high degree of specialization, on the development of nutraceutics from medicinal fungi. Therefore, the objective of the research carried out by the company is the development of Natural products For maintenance and Improvement of human health as adjuvant or preventive treatments.
Hifas Da Terra's commitment to human health and well -being translates into research and innovation for product development as nutraceutical, medical devices and drugs high quality and added value for the Integrative treatment of pathologies.
In addition to this clinical trial in breast cancer within the framework of the ‘Microimmunomama’ project, the Biotech is also the leader of the homologous project called ‘Micromarker’, in which another clinical trial whose promoter is the Galicia Sur Biomedical Foundation (Management Entity of the IIS Galicia Sur) in 140 patients with colorectal cancer has been launched. Currently, their clinical research studies are also carried out in other areas such as gastrointestinal, immunological, musculoskeletal system and mental and emotional health system.
Thus, the strong bet of Hifas da Terra for innovation, with more than the 62 % of its benefits invested in research and development, has led this Biotech to be a pioneer in the realization of high quality clinical trials and relevance to demonstrate the health benefits of natural products that develop medicinal fungi.
Hifas da Terra investigates the role of fungi in cancer and neurodegenerative, cardiovascular and autoimmune pathologies.